Source: BioCentury

Peloton Therapeutics: Merck bets on HIF2As with Peloton takeout ahead of planned listing

Read full article »
Peloton Therapeutics's Competitors | Peloton Therapeutics's News | Peloton Therapeutics's Financials
Stay up-to-date with the latest news on Peloton Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
John A. Josey's photo - President & CEO of Peloton Therapeutics

President & CEO

John A. Josey

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Peloton Therapeutics